Mizrahi Jacques
Hoofd Techniek/Wetenschap/O&O bij ELSALYS BIOTECH
Oorsprong van het eerstegraads netwerk van Mizrahi Jacques
Entiteit | Type entiteit | Industrie | |
---|---|---|---|
Aravis AG
Aravis AG Investment ManagersFinance Aravis AG (Aravis) is an independent venture capital firm, founded in 2001 by Jean-Philippe Tripet and headquartered in Muttenz, Switzerland.
21
| Private Company | Investment Managers | 21 |
Subsidiary | Pharmaceuticals: Major | 11 | |
LiMM Therapeutics SA
LiMM Therapeutics SA Financial ConglomeratesFinance LiMM Therapeutics SA operates as a biopharmaceutical corporation, that specializes in molecular cross-talk between neuronal and innate lymphoid cells within peripheral tissues. The firm develops medicines against inflammatory, infectious, and metabolic diseases. The company was founded by David Braga Malta and Henrique Veiga Fernandes and is headquartered in Paris, France.
5
| Holding Company | Financial Conglomerates | 5 |
Kymo Therapeutics Ltd.
Kymo Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Kymo Therapeutics Ltd. develops and commercializes therapeutic products . The company was founded on May 23, 2016 and is headquartered in Hatfield, the United Kingdom.
2
| Holding Company | Pharmaceuticals: Major | 2 |
Grafiek van bedrijven verbonden in de tweede graad
Connectie in verschillende bedrijven
Bedrijven verbonden met Mizrahi Jacques via zijn persoonlijke netwerk
Onderneming | Sector | Gelieerde personen | Hoofdpost |
---|---|---|---|
MERCK KGAA | Pharmaceuticals: Major | Corporate Officer/Principal | |
TRANSGENE | Biotechnology | Director of Finance/CFO Director/Board Member General Counsel Corporate Officer/Principal Chief Tech/Sci/R&D Officer | |
EUSA Pharma, Inc.
EUSA Pharma, Inc. Pharmaceuticals: MajorHealth Technology EUSA Pharma is a rapidly growing transatlantic specialty pharmaceutical company focused on in-licensing, developing and marketing late-stage oncology, pain control and critical care products. The company currently has eight products on the market, including Caphosol for the treatment of oral mucositis, a common and debilitating side-effect of radiation therapy and high-dose chemotherapy, ProstaScint for imaging the extent and spread of prostate cancer, Quadramet for the treatment of pain in patients whose cancer has spread to the bones, Erwinase and Kidrolase for the treatment of acute lymphoblastic leukemia and the antibiotic surgical implant Collatamp. EUSA also has several products in late-stage development, notably Collatamp topical, a gentamicin impregnated collagen sponge for the prevention and treatment of infected skin ulcers, and CollaRx bupivacaine implant for local post-surgical pain control. Founded in 2006, EUSA Pharma is supported by a consortium of leading life science capital investors, comprising TVM Capital, Essex Woodlands, 3i, Goldman Sachs, Advent Venture Partners, SV Life Sciences, NeoMed and NovaQuest. Since its foundation, the company has raised over $275 million, and completed several significant transactions, including the acquisitions of Cytogen Corporation, Talisker Pharma Ltd, the French biopharmaceutical company OPi SA and the European antibiotic and pain control business of Innocoll Pharmaceuticals Inc. As part of its rapid growth strategy the company has established commercial infrastructure in the US, a pan-European presence covering over 20 countries and a wider distribution network in a further 25 territories. EUSA Pharma plans to continue its aggressive program of acquisitions and in-licensing within its specialist areas of medical and geographic focus, in line with its ambitious target to create a rapidly growing $1 billion company by the beginning of the next decade. | Pharmaceuticals: Major | Corporate Officer/Principal | |
VARISCAN MINES LIMITED | Other Metals/Minerals | Chairman | |
Index Ventures SA
Index Ventures SA Investment ManagersFinance Index Ventures SA (Index Ventures) is a venture capital firm founded in 1996 by Neil Alexander Rimer, Gluseppe Zocco and Gerald Rimer. The firm is headquartered in Geneva, Switzerland. | Investment Managers | Private Equity Analyst | |
Seventure Partners SA
Seventure Partners SA Investment ManagersFinance Seventure Partners SA (Seventure) is a Venture Capital firm, a subsidiary of Natixis SA founded in 1997. Seventure Partners SA is headquartered in Paris. | Investment Managers | Chief Executive Officer Corporate Officer/Principal | |
Queen's University of Belfast | College/University | Doctorate Degree | |
University of Barcelona | College/University | Doctorate Degree | |
Escuela de Organización Industrial | College/University | Masters Business Admin | |
University of Basel | College/University | Doctorate Degree Doctorate Degree | |
SYMETIS SA | Biotechnology | Chief Executive Officer Director/Board Member | |
École Centrale Paris | College/University | Undergraduate Degree Undergraduate Degree | |
NanoDimension Management Ltd.
NanoDimension Management Ltd. Investment ManagersFinance NanoDimension Management Ltd is a venture capital firm founded in 2002 by Aymeric Sallin. The firm is headquartered in George Town. | Investment Managers | Private Equity Investor | |
S*BIO Pte Ltd.
S*BIO Pte Ltd. Pharmaceuticals: MajorHealth Technology S*BIO is a privately-held biotech company focused on the research and clinical development of novel targeted small molecule drugs for the treatment of cancer with leading programs around histone deacetylases (HDAC) and kinases. S*BIO's lead candidate, SB939, entered the clinic in 2007. SB1518, S*BIO's potent and orally-active JAK2 inhibitor, entered the clinic in 2008 and has received orphan drug designation from the U.S. FDA. S*BIO has entered into a development collaboration, and option & license agreement with Onyx Pharmaceuticals, Inc. to develop and commercialize SB1518 and its other novel JAK2 inhibitor, SB1578. S*BIO's SB1317, a novel multikinase inhibitor, is in pre-clinical development and under a worldwide exclusive license with Tragara Pharmaceuticals, Inc. for its development and commercialization. In line with its vision to be a leading fully-integrated oncology-focused biotech company in Asia Pacific, S*BIO has established a state-of-the-art R&D infrastructure, complemented by a strong clinical development team. S*BIO has strong links with a network of medical oncologists in Asia Pacific and its investors include EDB Investments' biomedical sciences subsidiary Bio*One Capital, Aravis Ventures, Novartis Bioventures and other international funds. In 2009, S*BIO received the BioSpectrum Editor's Choice, Emerging BioScience Company of Singapore Award. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Evolva SA
Evolva SA Miscellaneous Commercial ServicesCommercial Services Evolva SA is a Swiss-headquartered, international pharmaceutical biotech company focused on the discovery and development of drugs based on its distinctive and proprietary genetic chemistry platform. The company was founded in Switzerland in 2004 based on US/Danish technology. Evolva is headquartered in Allschwil/Basel with operations in Denmark, India and the USA. The Company has raised CHF 38.2 million of equity to date and employs 75 persons of whom 30 are based in Allschwil. The firm's strategy and business approach is based on five pillars that offer a sustainable development path for creating a successful company, which include Building a balanced portfolio. Evolva focuses on orally available small molecules in the belief that they are more convenient for patients and more cost-effective both from manufacture and administration points of view for the society, focus on differentiated pharmaceutical products with major benefits. Focusing on cardiovascular/renal and infectious diseases. Together they cause more than 50% of all deaths worldwide. Most of the top 20 pharmaceutical companies are active in both sectors, and all are active in one of the two sectors - hence widening Evolva's opportunities to partner. Building technology platform as the source of this differentiation. Evolva finds different structures with different properties from those found by the 99% of the industry that focuses on synthetic chemistry or proteins. Openness to unusual markets. The biotech business model has changed. As well as the established markets new opportunities arise in emerging countries such as India and China, and in adjacent sectors such as treatments against potential bio-terrorist and bio-warfare agents and the production of pharmaceutical and industrial chemical intermediates. Cost-effective implementation. Evolva places different functions around the globe according to where local conditions best suit. This approach both reduces Evolva's cost base and increases access to revenues, partners and talent. Evolva sees revenues and partners as important because they provide additional flexibility, resources and talent. Also, they provide important opportunities to better understand, and better meet, the needs of current and future customers. | Miscellaneous Commercial Services | Corporate Officer/Principal Corporate Secretary | |
Touchstone Innovations Investment Management Ltd.
Touchstone Innovations Investment Management Ltd. Investment ManagersFinance Touchstone Innovations Investment Management Ltd. is a Venture Capital firm, a subsidiary of Touchstone Innovations Ltd. founded in 1986. Touchstone Innovations Investment Management Ltd. is headquartered in London. | Investment Managers | Director/Board Member | |
University of Lyon | College/University | Undergraduate Degree Doctorate Degree | |
TXCELL | Miscellaneous Commercial Services | Chief Executive Officer General Counsel | |
Singapore Institute of Directors | Corporate Officer/Principal | ||
Genclis SA
Genclis SA Miscellaneous Commercial ServicesCommercial Services Genclis SA operates as a holding company with interest in providing research services to the medical and biotechnology firms. The company was founded by Jean Cinqualbre in 2006 and is headquartered in Vandoeuvre-les-Nancy, France. | Miscellaneous Commercial Services | Chief Executive Officer Director of Finance/CFO | |
ADOCIA | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Crescendo Biologics Ltd.
Crescendo Biologics Ltd. Miscellaneous Commercial ServicesCommercial Services Crescendo Biologics Ltd. engages in the development of new medicines based on antibody fragment technology. Its products in pipeline in dermatology include CB001, a transformational Humabody-based topical biologic for psoriasis which combines exceptional activity against a validated target with a topical route of delivery to avoid systemic side effects. The firm?s oncology products in pipeline include Humabody Multi-Specific T-Cell Engagers, Humabody Antibody Drug Conjugates and Immune Checkpoint Inhibitors. The company was founded by Michael Anthony Romanos, David Rayll Brown and John Bradshaw on November 13, 2007 and is headquartered in Cambridge, the United Kingdom. | Miscellaneous Commercial Services | Director/Board Member | |
Akamis Bio Ltd.
Akamis Bio Ltd. BiotechnologyHealth Technology Akamis Bio Ltd. operates as a biotechnology company which develops novel therapeutics that addresses cancer and other clinically unmet diseases. Its products include Enadenotucirev, Espindolol and AbEnAd. The firm also develops treatments based upon the research phase vaccine platform PolySTAR, which combines recombinant viral vectors with polymers to shield them from the immune system, and the research phase adjuvant and immunotherapeutic platform PolyMAP, which combines polymers with synthetic adjuvants to significantly enhance the effectiveness of vaccines. The company was founded by Andrew Justin Stewart Coats and Stefan D. Anker on November 17, 2006 and is headquartered in Abingdon, the United Kingdom. | Biotechnology | Director/Board Member | |
Maida Vale Associates Pte. Ltd. | Chief Executive Officer | ||
TopiVert Ltd.
TopiVert Ltd. BiotechnologyHealth Technology TopiVert Ltd. develops topical treatments for inflammatory diseases of the eye and gut. Its application is used in the treatment of asthma, chronic obstructive pulmonary disease, and cystic fibrosis and other inflammatory diseases of the lungs. The company was founded by Eric Charles Meldrum in 2011 and is headquartered in London, the United Kingdom. | Biotechnology | Director/Board Member | |
IP Group Plc /Venture Capital/
IP Group Plc /Venture Capital/ Investment ManagersFinance IP Group Plc /Venture Capital/ (IP Group) is a venture capital subsidiary of IP Group Plc founded in 2001. The firm is headquartered in London, United Kingdom. | Investment Managers | Private Equity Investor | |
Platine Pharma Services SAS
Platine Pharma Services SAS Medical/Nursing ServicesHealth Services Based in Lyon within the Center of excellence in Infectious Diseases, Platine Pharma Services is an essential source of immune information for scientists and clinicians. From protocol support to regulatory reports, the company designs, performs and interprets complex molecular and cellular assays. Platine actively supports the development of in-vitro diagnostic, cosmetic and therapeutic product candidates, highlighting key markers and features in both normal and pathological conditions, and guiding decisions at each development stage. Using state-of-the-art technologies such as multi-parametric flow cytometry, Singulex, Luminex, Mesoscale Discovery, ELISpot or ELISA, Platine Pharma Services offers a fit-for-purpose approach to its customers and partners. | Medical/Nursing Services | Director/Board Member Director/Board Member | |
Luminor Pacific Fund 1 Ltd.
Luminor Pacific Fund 1 Ltd. Investment ManagersFinance Luminor Pacific Fund 1 Ltd. seeks investment opportunities in the companies located in Asia Pacific region. The fund focuses in the companies operating in the fields of resources, renewable energy and recombinant technology sectors. It provides for private equity capital requirements. | Investment Managers | Director/Board Member | |
Amira Properties Sdn. Bhd.
Amira Properties Sdn. Bhd. Financial ConglomeratesFinance Part of Luminor Capital Pte Ltd., Amira Properties Sdn. Bhd. provides investment services. | Financial Conglomerates | Director/Board Member | |
Accentvest Sdn. Bhd.
Accentvest Sdn. Bhd. Financial ConglomeratesFinance Accentvest Sdn. Bhd. provides investment services. | Financial Conglomerates | Director/Board Member | |
Minoryx Therapeutics SL
Minoryx Therapeutics SL BiotechnologyHealth Technology Minoryx Therapeutics SL engages in the development of drugs for the orphan genetic diseases of the central nervous system. The company was founded by Marc Martinell, Joan Aymami, Nigel Ten Fleming and Xavier Barril in 2011 and is headquartered in Barcelona, Spain. | Biotechnology | Director/Board Member | |
MAAT PHARMA | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Biosingapore
Biosingapore Miscellaneous Commercial ServicesCommercial Services Biosingapore operates as an association of life science businesses. The private company is based in Singapore, Singapore. | Miscellaneous Commercial Services | Treasurer | |
VCPLUS LIMITED | Precious Metals | Director/Board Member | |
TargEDys SA
TargEDys SA BiotechnologyHealth Technology TargEDys SA develops microbiome-based solutions for appetite regulation. It provides humanity with easy means of regulating their eating behaviors for the third millennium. The company was founded by Pierre Dechelotte and Gregory Lambert 2011 and is headquartered in Paris, France. | Biotechnology | Director/Board Member Director/Board Member | |
Multiple Lodge Sdn. Bhd. | Director/Board Member | ||
Sg Securities Asia Ltd. | Corporate Officer/Principal | ||
Luminor Capital Australia Pty Ltd. | Director/Board Member | ||
Luminor Harbour Fund 1 Pte Ltd. | Director/Board Member | ||
Bio -harma & Life-Sciences Consulting SRL
Bio -harma & Life-Sciences Consulting SRL Miscellaneous Commercial ServicesCommercial Services Bio-harma & Life-Sciences Consulting SRL is a biotechnology research and development company based in Paris, France. Bio-harma & Life-Sciences Consulting SRL provides biotechnology research and development services. The French company was founded by David Liens and he has been the CEO since incorporation. | Miscellaneous Commercial Services | Chief Executive Officer | |
Vandria SA
Vandria SA Pharmaceuticals: MajorHealth Technology Vandria SA is a Swiss-based company that specializes in mitochondrial therapeutics. The company is based in Lausanne, Switzerland. The company is developing mitophagy inducers that rejuvenate cells to treat age-related and chronic diseases. Its lead program, VNA-318, is a brain-penetrant, patent-protected, mitophagy inducer that has shown to improve memory and learning and to have strong disease-modifying effects in models of neurodegenerative diseases such as Alzheimer's and Parkinson's disease. Vandria is also developing mitophagy-inducing small molecules to address muscle, lung, and liver diseases, as well as a separate program that targets ferroptosis. The company was founded by Patrick Aebischer, Chris Rinsch, and Johan Auwerx in 2021 and has raised $20.60m in venture finance. Klaus Dugi has been the CEO of the company since 2021. | Pharmaceuticals: Major | Director/Board Member | |
PEC LTD. | Engineering & Construction | Director/Board Member | |
Strongwind Holding AG
Strongwind Holding AG Electric UtilitiesUtilities Strongwind Holding AG owns and operates wind park. The company is headquartered in Zurich, Switzerland. | Electric Utilities | Director/Board Member Chairman Director/Board Member Director/Board Member |
Statistieken
Internationaal
Frankrijk | 13 |
Singapore | 12 |
Zwitserland | 10 |
Verenigd Koninkrijk | 7 |
Spanje | 4 |
Sectoraal
Health Technology | 17 |
Finance | 10 |
Consumer Services | 7 |
Commercial Services | 7 |
Non-Energy Minerals | 3 |
Operationeel
Director/Board Member | 155 |
Corporate Officer/Principal | 50 |
Private Equity Investor | 30 |
Founder | 21 |
Chief Executive Officer | 18 |
Sterkste connecties
Insiders | |
---|---|
Fatt Kah Foo | 34 |
Stéphane Boissel | 24 |
Guido Magni | 23 |
Dominique Takizawa | 23 |
Simon Jules Nebel | 23 |
Isabelle de Cremoux | 21 |
Jean-Philippe Tripet | 20 |
Eric Forquenot de la Fortelle | 19 |
Daniel Bach | 13 |
Jacques R. Essinger | 12 |
Johanna Holldack | 11 |
Rolf M. Zinkernagel | 10 |
Liliane Bronstein | 8 |
David Liens | 6 |
Emmanuel Savioz | 6 |
- Beurs
- Insiders
- Mizrahi Jacques
- Bedrijfsconnecties